Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immuneering CorpIMRX · Entity 5884 | CFO, TREASURER | May 12, 2022 | May 12, 2022 |
| Social Capital Suvretta Holdings Corp. IVDNAD · Entity 123913 | Director | June 29, 2022 | July 06, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immuneering Corp
Report date May 12, 2022 · Filed May 12, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 7,898 |
Reported balance
After 2022-05-12 transaction · row 1
1 source rowRow 1 · 2022-05-12 · Purchase · Acquired 1,000 · Balance 7,898 |
Social Capital Suvretta Holdings Corp. IV
Report date June 29, 2022 · Filed July 06, 2022
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 12, 2022 Filed May 12, 2022 17:37 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 1,000 | $4.42 | $4,420.00 |
DisclosureSEC source: 0001415889-22-004919 · form4-05122022_020511.xml · nonDerivative · entry 1 Amin Biren · CIK 0001870127 · CFO, TREASURER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,898 Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 17:35 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 70,050 | $0.00 Strike: $9.66 | $0.00 |
DisclosureSEC source: 0001415889-22-001330 · form4-02142022_020254.xml · derivative · entry 1 Amin Biren · CIK 0001870127 · CFO, TREASURER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,050 Underlying: Class A Common Stock · 70,050 shares Expires 2032-02-09 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2022, and will be fully vested and exercisable on January 1, 2026. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 06:04 UTC | Immuneering Corp IMRX · Entity 5884 | ConversionSeries B Preferred Stock · Derivative | 2,723 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-099723 · tm2123807-1_4seq1.xml · derivative · entry 3 Amin Biren · CIK 0001870127 · CFO, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 2,723 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 06:04 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 4,175 | $15.00 | $62,625.00 |
DisclosureSEC source: 0001104659-21-099723 · tm2123807-1_4seq1.xml · nonDerivative · entry 2 Amin Biren · CIK 0001870127 · CFO, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,898 Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 06:04 UTC | Immuneering Corp IMRX · Entity 5884 | ConversionClass A Common Stock | 2,723 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-099723 · tm2123807-1_4seq1.xml · nonDerivative · entry 1 Amin Biren · CIK 0001870127 · CFO, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,723 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.